Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome

Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome

(2022) Raphaele Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study

(2022) Yunzhi Zhufeng et al.   Frontiers in Cellular and Infection Microbiology

Low-dose interleukin-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation

(2022) Nicolas Tchitchek et al.   JCI Insight

Interleukin-2 and regulatory T cells in rheumatic diseases

(2021) Antonios G. A. Kolios et al.   Nature Reviews Rheumatology

Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA

(2020) Chetna Soni et al.   IMMUNITY

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

(2019) Jing He et al.   ANNALS OF THE RHEUMATIC DISEASES

Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome

(2018) Miao Miao et al.   ANNALS OF THE RHEUMATIC DISEASES

Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients

(2018) Hui Gao et al.   MEDICINE

Primary Sjögren’s Syndrome

(2018) Xavier Mariette et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-cell activity markers are associated with different disease activity domains in primary Sjögren’s syndrome

(2018) Katherine James et al.   RHEUMATOLOGY

Unknown

(2018)   Arthritis & Rheumatology

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

(2018) Michelle Rosenzwajg et al.   ANNALS OF THE RHEUMATIC DISEASES

The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome

(2017) Elizabeth J. Price et al.   RHEUMATOLOGY

A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren’s syndrome

(2016) Claudia Kedor et al.   CLINICAL RHEUMATOLOGY

IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells

(2016) Lin Gui et al.   CYTOKINE

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

(2016) Jing He et al.   NATURE MEDICINE

Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome

(2016) G. Nocturne et al.   Arthritis & Rheumatology

T Regulatory and T Helper 17 Cells in Primary Sjögren’s Syndrome: Facts and Perspectives

(2015) Alessia Alunno et al.   MEDIATORS OF INFLAMMATION

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

(2014) Raphaèle Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

(2014) Janice P Dutcher et al.   Journal for ImmunoTherapy of Cancer

Circulating Precursor CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh Cell Activity and Promote Antibody Responses upon Antigen Reexposure

(2013) Jing He et al.   IMMUNITY

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome

(2011) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

(2011) David Saadoun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

(2011) John Koreth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytokines in Sjogren's syndrome: potential therapeutic targets

(2010) N. Roescher et al.   ANNALS OF THE RHEUMATIC DISEASES

Cytokine regulation of natural killer cell effector functions

(2010) Norberto W. Zwirner et al.   BIOFACTORS

Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells

(2010) Y. Iwata et al.   BLOOD

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Primary Sjogren's syndrome: too dry and too tired

(2010) W. F. Ng et al.   RHEUMATOLOGY

EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome

(2009) R. Seror et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells

(2008) Katsuya Suzuki et al.   CYTOKINE